Rheumatology International

, Volume 32, Issue 6, pp 1711–1720 | Cite as

Role of matrix metalloproteinase-3 (MMP-3) and magnetic resonance imaging of sacroiliitis in assessing disease activity in ankylosing spondylitis

  • Eiman Soliman
  • W. Labib
  • G. El-tantawi
  • A. Hamimy
  • A. Alhadidy
  • A. Aldawoudy
Original Article


The objective of this study is to evaluate the role of MMP-3 and MRI in assessing disease activity in sacroiliac joints of AS patients in comparison to the conventional measures Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Serum MMP-3 was measured in 30 patients who fulfilled the modified New York criteria for AS and in ten healthy volunteers. AS patients were categorized into those having high or low MMP-3 according to a cut-off value = 7.1 ng/ml. MRI of the sacroiliac joints (SIJs) was performed on all patients. SIJs were evaluated for enhancement and subchondral bone marrow edema. Results of MMP-3 and findings on MRI were correlated with multiple clinical parameters including BASDAI, ESR and CRP. Serum MMP-3 was significantly elevated in AS patients with active disease. Elevated MMP-3 levels were significantly associated with high BASDAI (P = 0.046), but not with ESR or CRP. MRI showed bone marrow edema and enhancement of SIJs in 19/30 patients with one patient showing enhancement only. These MRI findings were not correlated with MMP-3, BASDAI, CRP or ESR. In conclusion, serum MMP-3 is an objective measure reflecting clinical disease activity in AS. Bone marrow edema and enhancement detected by MRI of SIJs is another objective measure of disease activity, but are not correlated with MMP-3 or the conventional parameters as BASDAI, ESR, or CRP. Although both MMP-3 and MRI can reflect disease activity in AS they seem to be unrelated, perhaps each is reflecting a different aspect of disease activity. MMP-3 and MRI should be considered together with BASDAI in assessing disease activity and in guiding the available recommendations for initiation of biologics in AS.


Ankylosing spondylitis Disease activity BASDAI MMP-3 MRI 


Conflict of interest

The authors declare no conflicts of interest.


  1. 1.
    Sengupta R, Stone MA (2007) The assessment of ankylosing spondylitis in clinical practice. Nat Clin Pract Rheumatol 3(9):496–503PubMedCrossRefGoogle Scholar
  2. 2.
    Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442–452. doi: 10.1136/ard.2005.041137
  3. 3.
    Garrett S, Jenkinson T, Kennedy G, BASDAI et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–91Google Scholar
  4. 4.
    Yildirim K, Erdal A, Karatay S et al (2004) Relationship between some acute phase reactants and the Bath ankylosing Spondylitis Disease Activity Index in patients with ankylosing spondylitis. South Med J 97:350–353PubMedCrossRefGoogle Scholar
  5. 5.
    Hembry RM, Bagga MR, Reynolds JJ et al (1995) Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 54:25–32PubMedCrossRefGoogle Scholar
  6. 6.
    Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274:21491–21494PubMedCrossRefGoogle Scholar
  7. 7.
    Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827–839PubMedCrossRefGoogle Scholar
  8. 8.
    MacNaul KL, Chartrain N, Lark M, Tocci MJ et al (1990) Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J Biol Chem 265:17238–17245PubMedGoogle Scholar
  9. 9.
    Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151–160PubMedGoogle Scholar
  10. 10.
    Ribbens C, Martin y Porras M, Franchimont N et al (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166PubMedCrossRefGoogle Scholar
  11. 11.
    Vandooren B, Kruithof E, Yu DT et al (2004) Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50:2942–2953PubMedCrossRefGoogle Scholar
  12. 12.
    Chen C, Lin K, Yu D et al (2006) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology 45:414–420PubMedCrossRefGoogle Scholar
  13. 13.
    Lukas C, Braun J, van der Heijde D et al (2007) Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J Rheumatol 34:862–70Google Scholar
  14. 14.
    Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J (1994) Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 37:1039–1045PubMedCrossRefGoogle Scholar
  15. 15.
    Bennett AN, Marzo-Ortega H, Emery P et al (2009) Diagnosing axial spondyloarthropathy. The new Assessment in SpondyloArthritis International Society criteria: MRI entering centre stage. Ann Rheum Dis 68:765–767PubMedCrossRefGoogle Scholar
  16. 16.
    Weber U, Maksymowych WP (2008) How does imaging help the clinician in the evaluation and management of spondyloarthritis? Skeletal Radiol 37:487–490PubMedCrossRefGoogle Scholar
  17. 17.
    Braun J, Landewe R, Hermann KG, Han J et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo controlled magnetic resonance imaging study. Arthritis Rheum 54:1646–1652PubMedCrossRefGoogle Scholar
  18. 18.
    van der Linden S, Valkenberg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRefGoogle Scholar
  19. 19.
    van Tubergan A, Debates I, Ryser L et al (2002) Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. Arthritis Rheum 47:242–248CrossRefGoogle Scholar
  20. 20.
    Jones SD, Steiner A, Calin A et al (1996) The Bath ankylosing spondylitis patient global score (BAS-G). Br J Rheumatol 35:66–71PubMedCrossRefGoogle Scholar
  21. 21.
    Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMedGoogle Scholar
  22. 22.
    Jenkinson T, Mallorie P, Whitelock H et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21:1694–1698PubMedGoogle Scholar
  23. 23.
    Dougados M, Hermann K-G, Landewé R et al (2009) The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68:ii1–ii44Google Scholar
  24. 24.
    Docherty P, Mitchell MJ, MacMillan L et al (1992) Magnetic resonance imaging in the detection of sacroiliitis. J Rheumatol 19:393–401PubMedGoogle Scholar
  25. 25.
    Lewis SM (2001) Miscellaneous tests. In: Lewis SM, Bum BJ, Bates I (eds) Dacie and Lewis practical haematology, 9th edn. Churchill Livingstone, London, pp 527–531Google Scholar
  26. 26.
    Taylor DJ, Cheung NT, Dawes PT (1994) Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 53:768–772PubMedCrossRefGoogle Scholar
  27. 27.
    Zochling J, Braun J (2005) Assessment of ankylosing spondylitis. Clin Exp Rheumatol 23:S133–S141PubMedGoogle Scholar
  28. 28.
    Calin A, Nakache JP, Geuguen A et al (1999) Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology 38:878–882PubMedCrossRefGoogle Scholar
  29. 29.
    Spoorenberg A, van Tubergen A, Landewe R et al (2005) Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology 44:789–795PubMedCrossRefGoogle Scholar
  30. 30.
    Spoorenberg A, van der Heijde D, de Klerk E, Dougados M et al (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26:980–984PubMedGoogle Scholar
  31. 31.
    Sheehan NJ, Slavin BM, Donovan MP et al (1986) Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute-phase proteins or protease inhibitors in ankylosing spondylitis. Br J Rheumatol 25:171–174PubMedCrossRefGoogle Scholar
  32. 32.
    Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F (2007) Acute-phase response clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine 74:249–253PubMedCrossRefGoogle Scholar
  33. 33.
    Ruof J, Stucki G (1999) Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 26:966e70Google Scholar
  34. 34.
    Chunhua Y, Gu J, Rihl M et al (2004) Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 51:691–699CrossRefGoogle Scholar
  35. 35.
    Wendling D, Cedoz J, Racadot E (2008) Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFa antagonist therapy. Joint Bone Spine 75(5):559–562PubMedCrossRefGoogle Scholar
  36. 36.
    Puhakka K, Jurik A, Schiottz-Christensenl B et al (2004) Magnetic resonance imaging of sacroiliitis in early seronegative spondylarthropathy. Abnormalities correlated to clinical and laboratory findings. Rheumatology 43:234–237PubMedCrossRefGoogle Scholar
  37. 37.
    Woo J, Lee H, Sung I et al (2007) Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. Rheumatology 34:1753–1759Google Scholar
  38. 38.
    Goh L, Suresh P, Gafoor A, Hughes P, Hickling P (2008) Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings. Clin Rheumatol 27(4):449–455PubMedCrossRefGoogle Scholar
  39. 39.
    Visvanathan S, Wagner C, Marini JC et al (2007) Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 67:511–517. doi: 10.1136/ard.2007.071605 Google Scholar
  40. 40.
    Jee W, McCauley T, Lee S et al (2004) Sacroiliitis in patients with ankylosing spondylitis: association of MR findings with disease activity. Magn Reson Imaging 22:245–250PubMedCrossRefGoogle Scholar
  41. 41.
    Jarrett SJ, Sivera F, Cawkwell LS, Marzo-Ortega H, McGonagle D, Hensor E, Coates L, O’Connor PJ, Fraser A, Conaghan PG, Emery P (2009) MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 68:1466–1469. doi: 10.1136/ard.2008.092213 Google Scholar
  42. 42.
    Bredella MA, Steinbach LS, Morgan S, Ward M, Davis JC (2006) MRI of the sacroiliac joints in patients with moderate to severe ankylosing spondylitis. AJR 187:1420–1426PubMedCrossRefGoogle Scholar
  43. 43.
    Song H, Rudwaleit M, Listing J et al (2009) Comparison of the BASDAI and the modified BASDAI (mini-BASDAI) in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis. 68(11):1701–1707. doi: 10.1136/ard.2008.099226
  44. 44.
    Lukas C, Landewé R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18–24. doi: 10.1136/ard.2008.094870 Google Scholar
  45. 45.
    van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R, for the Assessment of SpondyloArthritis international Society (ASAS) (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818. doi: 10.1136/ard.2008.100826 Google Scholar
  46. 46.
    Rudwaleit M, Schwarzlose S, Hilgert ES et al (2008) MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67:1276–1281PubMedCrossRefGoogle Scholar
  47. 47.
    Lord P, Farragher T, Lunt M et al (2010) Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology. Biol Register Rheumatol 49(3):563–570Google Scholar
  48. 48.
    Maksymowych W, Rahman P, Shojania K et al (2008) Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. Rheumatology 35:2030–2037Google Scholar
  49. 49.
    Maksymowych W, Poole A, Hiebert L et al (2005) Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 32:1911–1917PubMedGoogle Scholar
  50. 50.
    Maksymowych WP, Landewé R, Conner-Spady B et al (2007) Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56:1846–1853PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Eiman Soliman
    • 1
  • W. Labib
    • 2
  • G. El-tantawi
    • 2
  • A. Hamimy
    • 3
  • A. Alhadidy
    • 4
  • A. Aldawoudy
    • 5
  1. 1.Department of Internal Medicine and Rheumatology, Faculty of MedicineAlexandria UniversityAlexandriaEgypt
  2. 2.Department of Physical Medicine, Rheumatology and RehabilitationAlexandria UniversityAlexandriaEgypt
  3. 3.Department of RadiodiagnosisAlexandria UniversityAlexandriaEgypt
  4. 4.Department of Clinical PathologyAlexandria UniversityAlexandriaEgypt
  5. 5.Department of OrthopaedicsAlexandria University Student HospitalAlexandriaEgypt

Personalised recommendations